Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12539973 | 0.89 | HCAR2 (0.48) | HCAR2KDM1AKDM1BGRM2MEN1 | |
| SCHEMBL12541089 | 0.89 | HCAR2 (0.48) | HCAR2KDM1AKDM1BGRM2MEN1 | |
| SCHEMBL12539971 | 0.89 | HCAR2 (0.48) | HCAR2KDM1AKDM1BGRM2MEN1 | |
| SCHEMBL2505519 | 0.85 | HTR2C (0.40) | HCAR2ESR2HTR1ASLC6A2SLC6A4 | |
| SCHEMBL29487575 | 0.85 | HTR2C (0.40) | HCAR2ESR2HTR1ASLC6A2SLC6A4 | |
| SCHEMBL27267184 | 0.83 | ESR2 (0.47) | ESR2MEN1KMT2AGAAHTR2C | |
| SCHEMBL434606 | 0.83 | KDM1A (0.52) | HCAR2KDM1AKDM1BGRM2MEN1 | |
| SCHEMBL425265 | 0.79 | KDM1A (0.50) | HCAR2KDM1AKDM1BGRM2MEN1 | |
| SCHEMBL316350 | 0.79 | KDM4E (0.55) | KDM1AKDM1BGRM2KDM4EGAA | |
| SCHEMBL434672 | 0.79 | KDM4E (0.50) | HCAR2KDM1AKDM1BGRM2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673431-A1 | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | Novartis AG (CH) | 2026-01-07 | — | — | EP | disclosed |
| US-12129246-B1 | Hydroquinazoline derivatives for the treatment of a disease or disorder | NOVARTIS AG (CH) | 2024-10-29 | — | — | US | disclosed |
| US-20240336598-A1 | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-10-10 | — | — | US | disclosed |
| WO-2024180499-A1 | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS AG (CH) | 2024-09-06 | — | — | WO | disclosed |
| CN-109952300-B | 5-or 8-substituted imidazo [1,5-a ] pyridines | 百济神州有限公司 | 2022-01-18 | — | — | CN | disclosed |
| US-11179710-B2 | Direct palladium-catalyzed aromatic fluorination | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-11-23 | — | — | US | disclosed |
| US-11179710-B2 | Direct palladium-catalyzed aromatic fluorination | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3426654-B1 | DIRECT PALLADIUM-CATALYZED AROMATIC FLUORINATION | HARVARD COLLEGE (US) | 2021-10-20 | — | — | EP | disclosed |
| EP-3426654-B1 | DIRECT PALLADIUM-CATALYZED AROMATIC FLUORINATION | HARVARD COLLEGE (US) | 2021-10-20 | — | — | EP | disclosed |
| US-10882856-B2 | 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases | BEIGENE, LTD. (KY) | 2021-01-05 | — | — | US | disclosed |
| EP-3426654-A1 | DIRECT PALLADIUM-CATALYZED AROMATIC FLUORINATION | President and Fellows of Harvard College (US) | 2019-01-16 | — | — | EP | disclosed |
| WO-2018054365-A1 | NOVEL 5 or 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS SELECTIVE INHIBITORS OF INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES | BEIGENE, LTD. (KY) | 2018-03-29 | — | — | WO | disclosed |
| WO-2017156265-A1 | DIRECT PALLADIUM-CATALYZED AROMATIC FLUORINATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017156265-A1 | DIRECT PALLADIUM-CATALYZED AROMATIC FLUORINATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-09-14 | — | — | WO | disclosed |
| CN-102046633-B | Substituted spirocyclic cyclohexane derivatives | GRUENENTHAL GMBH | 2015-03-25 | — | — | CN | disclosed |
| EP-0998285-A4 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2003-01-08 | — | — | EP | disclosed |
| US-6255315-B1 | BENIGN PROSTATIC HYPERPLASIA | MERCK & CO., INC. | 2001-07-03 | — | — | US | disclosed |
| EP-0998285-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2000-05-10 | — | — | EP | disclosed |
| US-6037354-A | ADMINISTERING PHENYL-SUBSTITUTED THIAZOLIDIN-4-ONE OR OXAZOLIDIN-2-ONE DERIVATIVE TO TREAT BENIGN PROSTATE HYPERPLASIA; SIDE EFFECT REDUCTION | MERCK & CO., INC. (US) | 2000-03-14 | — | — | US | disclosed |
| WO-1998057641-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882856-B2 | 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases | IDO1, TPH1, IDO2 | HCAR2 583/4885KDM1A 209/4885KDM1B 1169/4885 |
| US-12129246-B1 | Hydroquinazoline derivatives for the treatment of a disease or disorder | RECQL, NRAS, RAB1A | HCAR2 470/4885KDM1A 3483/4885KDM1B 3159/4885 |
| US-11179710-B2 | Direct palladium-catalyzed aromatic fluorination | KRAS, NRAS, DDT | HCAR2 4610/4885KDM1A 480/4885KDM1B 894/4885 |
| US-20240336598-A1 | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | RECQL, NRAS, RAB1A | HCAR2 470/4885KDM1A 3483/4885KDM1B 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.